Kisspeptin
Kisspeptin is a KISS1-gene-derived neuropeptide that acts as a central regulator of the reproductive hormone axis. Signalling through its receptor KISS1R (also called GPR54), it sits upstream of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. The most commonly used research form is kisspeptin-10, a 10-amino-acid fragment retaining full receptor activity. It is studied primarily in academic and clinical-physiology settings and is not an approved therapy for any condition.
Side effects & risks
Kisspeptin's safety profile in humans is drawn largely from short-term research settings, so longer-term and real-world risks are not well characterised. In controlled studies it has generally been reported as well tolerated at investigational doses, with injection-site reactions among the more commonly noted effects. Because kisspeptin directly stimulates the reproductive hormone axis, the principal caution is unintended hormonal effects: shifts in LH, FSH, and sex steroids that could disrupt menstrual cycles, fertility, or endocrine balance. It should be regarded as contraindicated in pregnancy, in those trying to conceive without medical guidance, and in anyone with a hormone-sensitive condition or an untreated endocrine disorder, given the lack of safety data. Interactions with fertility treatments and other hormonal medications are plausible but poorly studied. Effects on mood and other centrally mediated processes have been noted in research and are not fully understood. These risks and side effects appear here above the fold because they are integral to understanding the peptide, not a footnote. Anyone considering kisspeptin should consult a qualified clinician before use, as it is neither an approved therapy nor validated for self-administration.
Latest studies
Kisspeptin-10/basal LH ratio improves differentiation of central precocious puberty and premature thelarche.
In girls being evaluated for early puberty, the ratio of blood kisspeptin-10 to basal LH distinguished true central precocious puberty from benign premature breast development with about 78% accuracy — potentially reducing the need for GnRH stimulation testing.
Comparison of the effects of atypical antipsychotics on decreased libido in zebrafish and their mechanisms.
This zebrafish study compared four antipsychotic medications to see which ones dampen mating behavior and why. Risperidone had the clearest negative effect, and one of the changes seen in its group was lower brain expression of the kiss2 gene, part of the kisspeptin signaling system that governs reproductive drive. Kisspeptin itself was not administered or studied as a therapy — it appears only as a gene readout. The findings are about antipsychotic side effects in fish, several steps removed from human relevance.
The endogenous ghrelin antagonist, LEAP2, accelerates puberty onset in conditions of early obesity.
This study examines LEAP2, a liver-derived peptide that blocks the ghrelin receptor, and its effect on the timing of puberty. Girls with obesity before puberty had elevated circulating LEAP2, as did an animal model of overweight with early puberty. Injecting LEAP2 into the brains of young female rats raised luteinizing hormone and, given repeatedly, advanced the onset of puberty - including in food-restricted animals. The mechanism runs through kisspeptin: LEAP2 increased hypothalamic Kiss1 expression and dampened ghrelin's effect on calcium activity in Kiss1 neurons, the cells that drive GnRH release.
Reported protocols (with caveats)
Reported use is confined to research and investigational settings, and kisspeptin is described as research use only. In published human physiology studies, kisspeptin-10 has most often been given intravenously as a bolus or continuous infusion, with doses frequently reported in the range of roughly 0.3 to a few micrograms per kilogram, allowing precise control of exposure. Some studies and community reports describe subcutaneous injection as an alternative route. Frequency in the literature varies from single acute challenges to repeated or pulsatile dosing designed to mimic natural GnRH pulses. Because these protocols come from controlled research environments with monitoring, they are not directly transferable to unsupervised use and are reported here for informational purposes only, never as a recommendation.